Compare NCA & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCA | AQST |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.3M | 809.3M |
| IPO Year | N/A | 2018 |
| Metric | NCA | AQST |
|---|---|---|
| Price | $8.80 | $6.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 59.6K | ★ 2.4M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,397,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $52.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.77 | $2.12 |
| 52 Week High | $9.12 | $7.55 |
| Indicator | NCA | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 33.84 | 52.76 |
| Support Level | $8.77 | $5.99 |
| Resistance Level | $8.94 | $6.44 |
| Average True Range (ATR) | 0.10 | 0.32 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 5.26 | 54.73 |
Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.